# Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients

> **NCT00327249** · PHASE1,PHASE2 · COMPLETED · sponsor: **AmpliMed Corporation**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** imexon

## Key facts

- **NCT ID:** NCT00327249
- **Lead sponsor:** AmpliMed Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2006-07
- **Final completion:** 2008-01
- **Target enrollment:** — (—)
- **Last updated:** 2009-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00327249

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00327249, "Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00327249. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*